Inhibition of Tau by Phytocompounds and Extracts from Medicinal Plants

Aisha Altaf,Muhammad Kazim Zargham,Abrar HUssain,Amanullah Lail,Fahad Sultan Sheikh,Muhammad Hanif Bangash

DOI: https://doi.org/10.55627/ppc.001.01.0101

2021-12-29

Abstract:Alzheimer's disease (AD) is the most common type of dementia, an irreversible neurodegenerative disease that worsens over time. It frequently affects the elderly population, and, therefore, its prevalence is soaring in countries with a high proportion of the aging population. The incidence of AD is likely to increase further with increasing life expectancy throughout the world. There is still no sight of therapies that could stop or slow the progression of AD despite the significant expansion in our understanding of the disease at molecular, cellular, and system levels in the last 50 years. The only medications approved by the Food and Drug Administration (FDA) for the treatment of AD are acetylcholinesterase inhibitors (donepezil, galantamine, tacrine, and rivastigmine) and glutamate receptor antagonist (memantine). Apart from acetylcholinesterase inhibition, another important therapeutic target for treating AD is the inhibition of hyperphosphorylation of tau proteins leading to the formation of neurofibrillary tangles. Extensive research following this approach has led to the rationally designed synthetic and potent tau inhibitors, several of which are in clinical trials. However, a high failure rate of the tau inhibitors in the clinical trials necessitates finding a different source of tau inhibitors. In this review, we discuss the most promising phytocompounds and plant extracts showing potent tau inhibitory activities. Future research directions are suggested, and recommendations are made to expand the use of medicinal plants and their formulations to prevent, mitigate and treat AD.